Observational analysis shows therapeutic benefit from Trop-2.2 directed radiopharmaceuticals in pancreatic cancer, suggesting promising future treatments.
Here, we provide several direct and pretargeted radiopharmaceutical variants yielding therapeutic benefit for a Trop-2.2 expressing pancreatic cancer model.
No takes yet. Share an insight, caveat, or question.
Pratt et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: